VectorBuilder Secures European Patent for MiniVec™, a Plasmid Backbone Advancing Safety and Manufacturability in Genetic Medicine
Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines
Chicago, IL – May 5, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced that its MiniVec™ plasmid system has been granted a European patent, marking a significant milestone for the company’s proprietary plasmid DNA technology and reinforcing its position at the forefront of gene delivery innovation.
As cell and gene therapies move toward clinical and commercial scale, attention is shifting to the materials that support them. Plasmid design is now a critical factor in how therapies are manufactured, reviewed, and delivered. Rather than iterating incrementally on legacy designs, VectorBuilder focuses on addressing foundational constraints in gene delivery systems: reliance on antibiotic resistance genes, dependence on chemical selection systems during manufacturing, and the presence of extraneous protein-coding sequences that can contribute to cellular burden and immunogenicity. This approach reflects a broader shift in the field toward improving outcomes by refining vector design at the earliest stages of development.
Designed to streamline therapeutic development, MiniVec™ eliminates the need for antibiotic selection and reliance on chemical additives for plasmid maintenance, while avoiding protein-coding elements commonly found in bacterial-derived plasmids. The European patent covers the underlying plasmid system design and associated production approaches of MiniVec™, providing formal recognition of the novelty of this design architecture and its applicability to modern genetic medicine development. It is expected to support ongoing patent considerations in other major markets, such as the United States, Australia, Japan, Korea, and China.
“This patent reflects a fundamental shift in how plasmid systems can be designed for clinical use,” said Dr. Bruce Lahn, Chief Scientist of VectorBuilder. “Many of the challenges developers encounter later, whether in manufacturing, safety, or regulatory review, can be traced back to early design decisions. MiniVec™ was developed to remove these constraints at the source, improving how plasmids perform across the entire development pipeline.”
The development of MiniVec™ reflects how expectations for plasmid systems are evolving, with increasing emphasis on manufacturability, consistency, and patient safety across both clinical development and large-scale production.
Manufacturing efficiency at scale
MiniVec™ is optimized to simplify plasmid production while improving output. Its miniaturized backbone supports antibiotic-free and additive-free selection and fermentation, reducing process complexity in GMP environments. In industrial settings, this translates into consistent yield gains across vector types, averaging 3.5× higher by mass and 4.2× by molar quantity. Notably, these gains increase at manufacturing scale, directly lowering the cost of goods for GMP-grade plasmid production.
Performance across therapeutic applications
The reduced prokaryotic content of MiniVec™ contributes to measurable performance improvements across multiple applications. Studies show 3.4× higher lentiviral titers, 1.8× higher CRISPR-mediated genome integration activity, and consistent gains across transposon systems. In DNA vaccine models, MiniVec™ achieved 2.5× higher antibody titers. In cell therapy workflows, it delivered a 3.4× improvement in T-cell electroporation efficiency compared to traditional plasmids, with direct implications for CAR-T manufacturing throughput and dose consistency.
Safety profile and regulatory alignment
MiniVec™ has been systematically evaluated in vivo, including acute and repeated-dose studies assessing hematological, biochemical, and organ-level parameters, with no adverse effects observed. Empty backbone constructs showed no detectable immune activation, including no antibody response and no elevation in IFN-γ or IL-2. This profile aligns with FDA and EMA expectations to remove antibiotic resistance genes and unnecessary genetic elements, supporting the development of clinically relevant plasmid systems.
“The industry is moving toward more controlled and better-defined genetic systems,” said Dr. Lahn. “MiniVec™ is designed with that trajectory in mind, providing a plasmid backbone that meets the practical demands of manufacturing while addressing the safety and consistency expectations of regulators and clinicians.”
The European patent milestone highlights the potential of MiniVec™ across multiple areas of genetic medicine, including cell and gene therapy, DNA vaccine development, and emerging in vivo therapeutic approaches. In addition, its simplified and antibiotic-free design is advantageous in fields such as food-alternative biotechnology, where regulatory requirements for genetic materials are particularly stringent. As demand for scalable, regulatory-ready plasmid systems grows, MiniVec™ is positioned to play an increasingly important role in supporting the next generation of genetic medicines and biologics.
“With the European patent now in place, we are focused on expanding access to MiniVec™ and supporting its adoption across both research and clinical pipelines,” said Dr. Lahn. “This is about establishing a more refined standard for how genetic materials are designed, manufactured, and applied in real-world settings.”
The scientific basis of MiniVec™, outlining its design and performance across multiple applications, is detailed in a scientific preprint available on bioRxiv.
About VectorBuilder
VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development, and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities, and state-of-the-art GMP manufacturing facilities. With leading R&D and CDMO capabilities, the VectorBuilder team strives to provide the most effective gene-delivery solutions and develop innovative tools for life sciences research and genetic medicine.
